Sunday, November 11, 2018 11:19:24 AM
https://ir.oncosec.com/press-releases/detail/1957/data-from-oncosecs-oms-100-clinical-trial-accepted-for
Edit: see here
https://propthink.com/whats-next-for-oncosec-following-premature-melanoma-data/ and esp. the conclusion ("... a market cap of ~$60 million ... about $35M in cash. With early TNBC data in December and updated melanoma data sometime in Q1 2019, we think selling at a panic point is foolish."). Please make your own opinion. The TNBC data is the n=10 sample and the article states that this might only be interesting if some more than the two already known patients received some checkpoint inhibitor therapy (currently we have no hints of this). The update on Pisces (expected by the article in Q1 2019) will be much more, highly relevant.
Besides that there theoretically could be some preclinical results (mouse data) on the next-gen therapy, but usually even these are presented in the context of a medical congress. And I would not call these too much of a catalyst (a little, but not as much as real trial data).
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM